New drug combo tested to protect transplanted hearts
NCT ID NCT03292861
Summary
This study tests whether adding a drug called Thymoglobulin to standard anti-rejection medications helps prevent complications in new heart transplant patients. About 60 first-time transplant recipients will be randomly assigned to receive either the standard treatment or the standard treatment plus Thymoglobulin for five days after surgery. Researchers will monitor patients for one year to see if the added drug reduces rejection and other problems while checking for side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART TRANSPLANTATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cedars-Sinai Medical Center
Los Angeles, California, 90048, United States
-
Kaiser Permanente Los Angeles Medical Center
Los Angeles, California, 90027, United States
Conditions
Explore the condition pages connected to this study.